Table 2.
Univariate analysis of factors that influence transplant outcomes.
| Outcome and potent factors, % | All patients | P | Myeloid cohort | P | Lymphoid cohort | P |
|---|---|---|---|---|---|---|
| 1. EBV viremia* | ||||||
| Myeloid vs Lymphoid | 28.9 vs 47.1 | 0.001 | ||||
| ATG-G vs ATG-F | 58.6 vs 32.2 | 0.0003 | 48.0 vs 24.8 | 0.009 | 75.0 vs 42.1 | 0.003 |
| Male vs Female | 42.7 vs 29.1 | 0.029 | 35.1 vs 21.5 | 0.087 | 52.5 vs 40.0 | 0.177 |
| KIR2DS2+ vs KIR2DS2− | 43.5 vs 35.0 | 0.199 | 25.0 vs 29.7 | 0.643 | 63.2 vs 43.5 | 0.078 |
| 2. CMV viremia* | ||||||
| ATG-G vs ATG-F | 78.1 vs 62.4 | 0.003 | 72.0 vs 64.1 | 0.199 | 87.5 vs 60.4 | 0.001 |
| KIR2DS1+ vs KIR2DS1− | 67.5 vs 63.8 | 0.935 | 77.6 vs 59.1 | 0.029 | 52.9 vs 70.0 | 0.030 |
| KIR2DS3+ vs KIR2DS3− | 63.4 vs 65.4 | 0.695 | 79.2 vs 62.7 | 0.191 | 41.2 vs 69.0 | 0.057 |
| KIR3DS1+ vs KIR3DS1− | 67.9 vs 63.6 | 0.997 | 78.0 vs 58.7 | 0.041 | 52.9 vs 70.0 | 0.030 |
| R-L C (mismatch vs match) | 62.5 vs 71.4 | 0.079 | 63.3 vs 70.5 | 0.267 | 61.5 vs 73.1 | 0.151 |
| 3. Grade II-IV aGVHD* | ||||||
| High/Very high risk vs Low/Int risk | 41.1 vs 30.6 | 0.080 | 38.8 vs 25.8 | 0.068 | 45.8 vs 36.3 | 0.454 |
| MAC vs RIC | 35.2 vs 7.7 | 0.041 | 31.6 vs 11.1 | 0.178 | 40.0 vs 0.0 | 0.125 |
| R-L C (mismatch vs match) | 31.25 vs 40.0 | 0.256 | 29.6 vs 31.8 | 0.853 | 33.3 vs 53.9 | 0.095 |
| 4. Moderate to severe cGVHD* | ||||||
| KIR2DS2+ vs KIR2DS2− | 6.5 vs 19.2 | 0.048 | 7.4 vs 20.3 | 0.133 | 5.3 vs 17.7 | 0.197 |
| KIR2DS3+ vs KIR2DS3− | 7.3 vs 18.7 | 0.083 | 12.5 vs 19.0 | 0.487 | 0.0 vs 18.4 | 0.057 |
| 5. 3-yr CIR | ||||||
| Myeloid vs Lymphoid | 17.3 vs 26.2 | 0.087 | ||||
| High/Very high risk vs Low/Int risk | 32.9 vs 16.1 | 0.002 | 26.5 vs 12.4 | 0.031 | 45.8 vs 20.4 | 0.009 |
| CR1 vs >CR1 | 16.5 vs 33.9 | 0.002 | 13.6 vs 25.7 | 0.070 | 23.5 vs 36.4 | 0.202 |
| iKIR-HLA C variation (D vs U+I) | 38.1 vs 17.5 | 0.005 | 40.0 vs 13.5 | 0.004 | 35.8 vs 23.5 | 0.317 |
| 6. 3-yr NRM | ||||||
| Myeloid vs Lymphoid | 2.8 vs 9.9 | 0.024 | ||||
| High/Very high risk vs Low/Int risk | 1.4 vs 7.7 | 0.057 | 2.0 vs 3.2 | 0.683 | 0.0 vs 12.8 | 0.070 |
| iKIR-HLA C variation (D vs U+I) | 4.7 vs 6.0 | 0.745 | 10.0 vs 1.6 | 0.037 | 0.0 vs 12.7 | 0.078 |
| KIR2DS3+ vs KIR2DS3− | 0.0 vs 7.0 | 0.086 | 0.0 vs 3.4 | 0.362 | 0.0 vs 11.8 | 0.145 |
| KIR B/x vs KIR AA | 2.9 vs 7.9 | 0.112 | 0 vs 4.9 | 0.079 | 7.1 vs 11.7 | 0.497 |
| 7. 3-yr OS | ||||||
| Myeloid vs Lymphoid | 81.6 vs 67.7 | 0.016 | ||||
| ATG-G vs ATG-F | 75.5 vs 75.8 | 0.861 | 92.0 vs 79.3 | 0.147 | 49.2 vs 71.0 | 0.041 |
| High/Very high risk vs Low/Int risk | 67.0 vs 79.3 | 0.036 | 71.4 vs 87.1 | 0.029 | 58.3 vs 70.5 | 0.202 |
| CR1 vs >CR1 | 79.7 vs 64.5 | 0.010 | 85.8 vs 72.0 | 0.053 | 72.4 vs 50.0 | 0.025 |
| iKIR-HLA C variation (D vs U+I) | 65.1 vs 77.9 | 0.093 | 55.0 vs 86.0 | 0.0006 | 73.9 vs 65.9 | 0.418 |
| 8. 3-yr DFS | ||||||
| Myeloid vs Lymphoid | 79.9 vs 63.9 | 0.006 | ||||
| ATG-G vs ATG-F | 73.2 vs 73.3 | 0.835 | 78.3 vs 88.0 | 0.293 | 50.0 vs 66.5 | 0.085 |
| High/Very high risk vs Low/Int risk | 65.7 vs 76.2 | 0.080 | 71.4 vs 84.4 | 0.066 | 54.2 vs 66.8 | 0.218 |
| CR1 vs >CR1 | 76.7 vs 63.0 | 0.024 | 83.3 vs 72.0 | 0.107 | 67.7 vs 50.0 | 0.085 |
| iKIR-HLA C variation (D vs U+I) | 57.3 vs 76.5 | 0.016 | 50.0 vs 84.9 | 0.0001 | 64.2 vs 63.9 | 0.813 |
*Estimations of cumulative incidence are given at 100 days post-HSCT for aGVHD; 180 days post-HSCT for EBV and CMV viremia; 3 years post-HSCT for cGVHD.
Potent factors with p < 0.10 were in bold type.